Prevention and Prophylaxis of GVHD

Download this slideset to discover the latest evidence on GVHD prevention and prophylaxis.
Nelson Chao, MD, MBA
Format: Microsoft PowerPoint (.ppt)
File Size: 2.13 MB
Released: December 2, 2020


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Incyte Corporation

Related Content

Phase III BMT CTN 1703 trial of cyclophosphamide, tacrolimus, and mycophenolate mofetil for prevention of GVHD following alloSCT, presented at ASH 2022 and reported by Clinical Care Options (CCO)

Released: December 15, 2022

GVHD experts address key questions about the treatment of patients with graft versus host disease in this commentary from Clinical Care Options (CCO)

Corey Cutler, MD, MPH, FRCPC Released: May 4, 2022

Expert-selected summary slides on graft-versus-host disease to help diagnose and manage your patients with GVHD, from Clinical Care Options (CCO).

Corey Cutler, MD, MPH, FRCPC David Miklos, MD, PhD Robert Zeiser, MD Released: February 8, 2022

On-demand Clinical Care Options (CCO) webcast: expert faculty discuss treatment options for B-cell lymphomas, including updates from ASH 2021

Julie M. Vose, MD, MBA
Program Director
Brad S. Kahl, MD John P. Leonard, MD
Physicians: maximum of 2.25 AMA PRA Category 1 Credits Released: February 7, 2022 Expired: February 6, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings